SCHEMBL510562

SCHEMBL510562

Cc1[nH]c(C(=O)O)c(Cl)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.42
DAO P14920 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3117191 0.84 HCAR2 (0.41) HCAR2
SCHEMBL5322610 0.84 ALDH1A1 (0.57)
SCHEMBL24709647 0.81 CYP1A2 (0.50) DAO
SCHEMBL3114362 0.81 DAO (0.36) HCAR2DAO
SCHEMBL401252 0.80 HCAR2 (0.38) HCAR2
SCHEMBL3111450 0.79 TOP2A (0.43) DAO
SCHEMBL1919419 0.77 CYP1A2 (0.41) HCAR2
SCHEMBL510531 0.76 KDM4E (0.49) HCAR2
SCHEMBL3399851 0.76 KDM4E (0.44) HCAR2
SCHEMBL11828305 0.75 JAK2 (0.32) HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258342-B2 Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria UNIVERZA V LJUBLJANI (SI) 2025-03-25 US disclosed
US-20250002455-A1 NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY UNIV LJUBLJANI (SI) 2025-01-02 US disclosed
CN-118993926-A Preparation method of chiral amino acid 香港大学 2024-11-22 CN disclosed
US-20240383842-A1 METHODS OF PREPARING CHIRAL AMINO ACIDS Laboratory for Synthetic Chemistry and Chemical Biology Limited (CN) 2024-11-21 US disclosed
US-20240351999-A1 PYRROLYLACYLPIPERIDYLAMINE COMPOUND AND USE THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2024-10-24 US disclosed
EP-4353716-A1 PYRROLE ACYL PIPERYLHYDRAZINE COMPOUND AND USE THEREOF Institute of Materia Medica, Chinese Academy of Medical Sciences (CN) 2024-04-17 EP disclosed
CN-117843552-A Resolution method of cis-4-amino-3-methoxypiperidine-1-formate optical isomer 中国医学科学院药物研究所 2024-04-09 CN disclosed
CN-115466246-B Pyrrole amide piperidine amine compound and application thereof 中国医学科学院药物研究所 2024-02-06 CN disclosed
EP-4263503-A1 NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY Univerza V Ljubljani (SI) 2023-10-25 EP disclosed
WO-2022258038-A1 PYRROLE ACYL PIPERYLHYDRAZINE COMPOUND AND USE THEREOF 中国医学科学院药物研究所 2022-12-15 WO disclosed
EP-1856044-A2 PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS AstraZeneca AB (SE) 2007-11-21 EP disclosed
EP-1853586-A1 ANTIBACTERIAL PIPERIDINE DERIVATIVES AstraZeneca AB (SE) 2007-11-14 EP disclosed
EP-1664025-B1 PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2007-09-19 EP disclosed
US-20060223801-A1 Pyrrol derivatives with antibacterial activity ASTRAZENECA AB (SE) 2006-10-05 US disclosed
WO-2006092599-A2 PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS ASTRAZENECA AB (SE) 2006-09-08 WO disclosed
WO-2006092608-A1 TRICYCLIC DERIVATIVES OF AZETIDINE AND PYRROLE WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2006-09-08 WO disclosed
WO-2006087543-A1 ANTIBACTERIAL PIPERIDINE DERIVATIVES ASTRAZENECA AB (SE) 2006-08-24 WO disclosed
WO-2006087548-A2 PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS ASTRAZENECA AB (SE) 2006-08-24 WO disclosed
EP-1664025-A1 PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY AstraZeneca AB (SE) 2006-06-07 EP disclosed
WO-2005026149-A1 PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223801-A1 Pyrrol derivatives with antibacterial activity PEF1, PEPD, PELP1 HCAR2 4666/4885DAO 1965/4885
US-20250002455-A1 NEW N-PHENYLPYRROLAMIDE INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV WITH ANTIBACTERIAL ACTIVITY TOP1, TOP2A, TOP2B HCAR2 4095/4885DAO 2149/4885
US-20240383842-A1 METHODS OF PREPARING CHIRAL AMINO ACIDS BCAT1, BCAT2, ME1 HCAR2 2260/4885DAO 7/4885
US-20240351999-A1 PYRROLYLACYLPIPERIDYLAMINE COMPOUND AND USE THEREOF AADAT, PKD1, PCTP HCAR2 3566/4885DAO 404/4885
US-12258342-B2 Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria TOP1, TOP2A, TOP2B HCAR2 4693/4885DAO 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.